Clinical

This new study confirms the noninferiority of extended dosing intervals for psoriasis control in super responders.

Patients with endometriosis have a 4.2-fold greater ovarian cancer risk, highlighting the need for further research into the biological links between endometriosis subtypes and ovarian cancer.

New therapies to treat EGFR-mutated non–small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitors (TKIs) are needed to address EGFR TKI resistance after osimertinib.

A session on the final day of the 2024 Congress of the American Society of Preventive Cardiology explored the connections between autoimmune disease and cardiac events.

Aravindhan Veerapandiyan, MD, of the Division of Pediatric Neurology at the University of Arkansas for Medical Sciences, discussed the Duchenne muscular dystrophy (DMD) therapy landscape and barriers to treatment access.

A debate on whether testing Lp(a) levels is actionable in primary prevention today offered lively discussion at the 2024 Congress of the American Society for Preventive Cardiology, being held in Salt Lake City, Utah.

Researchers believe that in their revised 4-factor model to predict patient outcomes in chronic lymphocytic leukemia (CLL), CD49d tops lactate dehydrogenase.

A joint session with the Society for Cardiovascular Computed Tomography (SCCT) took place on the first day of the American Society for Preventive Cardiology 2024 Congress in Salt Lake City, Utah.

Steve Feldman, MD, PhD, of Wake Forest University School of Medicine, considers dupilumab the "gold standard" for itch control in patients with atopic dermatitis due to its minimal adverse effects.

Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.

Jonathan Silverberg, MD, PhD, MPH, examines the significant effects of chronic skin conditions such as atopic dermatitis and prurigo nodularis on patients' well-being, emphasizing the crucial role of prompt diagnosis in managing these impactful dermatologic diseases.

Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).

An exon-skipping technique using dual single-guide RNA/Cas9 ribonucleoproteins targeted at 3 novel COL7A1 exons with pathogenic heterozygous mutations achieved exon deletion rates of up to 95%.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies.

Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.

The panel explores how IPF affects patient productivity and its contribution to the disease's overall economic burden.

Decision-making factors surrounding optimal IPF treatment selection are evaluated by Justin Oldham, MD, MS.

An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.

Justin Oldham, MD, MS, discusses the current standard of car in treating idiopathic pulmonary fibrosis and the role of non-pharmacologic therapies.

Dr Nathan provides his final thoughts regarding IPF management.

Dr Nathan discusses the trajectory of IPF management.

Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.

Dr Nathan highlights the role of PDE4B inhibitors in IPF management.

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.

A health care provider outlines treatment objectives and supportive interventions for managing Friedreich ataxia, addressing associated comorbidities and symptoms in clinical settings.

Steve Feldman, MD, PhD, of Wake Forest University School of Medicine, discusses various effective treatments for alleviating itch in patients with atopic dermatitis (AD), including dupilumab and Janus kinase (JAK) inhibitors.

Inflammatory markers can indicate treatment efficacy and predict super-responder status in patients with psoriasis treated with biologics, according to one study.

A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).

The Shield blood test developed by Guardant has been approved by the FDA as a primary screening option for colorectal cancer, providing a more convenient method of screening.

In their concluding remarks, the expert panel shares insights and provides recommendations to help practicing clinicians optimize atopic dermatitis patient care.